U.S. markets closed

Abbott Laboratories (ABT)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
123.50+0.90 (+0.73%)
At close: 4:04PM EDT

123.50 0.00 (0.00%)
After hours: 6:21PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close122.60
Bid123.99 x 1100
Ask123.97 x 1100
Day's Range122.51 - 124.80
52 Week Range86.16 - 128.54
Avg. Volume5,348,583
Market Cap218.784B
Beta (5Y Monthly)0.70
PE Ratio (TTM)38.69
EPS (TTM)3.19
Earnings DateJul 14, 2021 - Jul 19, 2021
Forward Dividend & Yield1.80 (1.47%)
Ex-Dividend DateApr 14, 2021
1y Target Est135.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
19% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    UPDATE 3-Quest sees waning demand for COVID-19 tests, rebound in core U.S. business as pandemic subsides

    Quest Diagnostics Inc on Thursday reported a first-quarter profit that exceeded Wall Street expectations as a recovery in its non-COVID-19 businesses offset a slowdown in coronavirus testing. Quest, Abbott Laboratories, and others in the sector have benefited from surging demand for COVID-19 testing, bringing in billions in sales last year. "We continue to expect the decline in clinical demand for COVID-19 molecular testing in the second half of 2021 versus our expectations for the first half," Mark Guinan, Quest's chief financial officer, said during an investor call to discuss the quarterly results.

  • Motley Fool

    Which Stocks Are the Biggest Losers From Sinking COVID Testing Rates?

    In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss which stocks could be the biggest losers from this trend. Keith Speights: Now I came across another story recently, and in some ways it's surprising. While increasingly more Americans are receiving COVID-19 vaccines, the rates of COVID testing are falling pretty significantly in the United States.

  • 3 Things to Cheer About in Abbott's Earnings Report
    Motley Fool

    3 Things to Cheer About in Abbott's Earnings Report

    Abbott Laboratories (NYSE: ABT) disappointed some investors after first-quarter revenue lagged behind analysts' estimates. Investors probably were hoping that Abbott's coronavirus diagnostics along with the strength of its star product -- the FreeStyle Libre continuous glucose monitoring system -- would offer revenue a bigger push. Abbott's revenue still rose more than 35% to $10.5 billion in the first quarter.